Other actionable mutations have been detected in patients with NSCLC which affect the epidermal growth factor receptor (EGFR), BRAF, ERBB2, MET and gene fusions involving ROS1, RET or NTRK1–3 [5]. Here, EGFR is linked to non-small cell lung carcinoma.